Table 2.
Utilities and costs
| Model parameters | Base-case value (Range) | Distribution | Reference |
|---|---|---|---|
| Utility weights | |||
| F0–F3 | 0.904 (0.723–1) | Beta | [20] |
| SVR after F0–F3 fibrosis | 0.912 (0.730–1) | Beta | [21] |
| F4 | 0.877 (0.702–1) | Beta | [20] |
| SVR after F4 | 0.912 (0.730–1) | Beta | [20] |
| Decompensated cirrhosis | 0.848 (0.678–1) | Beta | [20] |
| HCC | 0.867 (0.694–1) | Beta | [20] |
| Liver transplant | 0.852 (0.682–1) | Beta | [20] |
| After liver transplant | 0.910 (0.728–1) | Beta | [20] |
| DT annualized decrement | 0.029 (0.023–0.035) | Beta | [7] |
| TT annualized decrement | 0.044 (0.035–0.052) | Beta | [7] |
| Cost (2013 €) | |||
| F0–F3 | 522 (±20%) | Gamma | [30] |
| SVR after F0–F3 fibrosis | 0 | – | Assumption |
| F4 | 1512 (±20%) | Gamma | Assumption |
| SVR after F4 | 1512 (±20%) | Gamma | [31] |
| Decompensated cirrhosis | 6350 (±20%) | Gamma | [31] |
| HCC | 12 744 (±20%) | Gamma | [31] |
| Liver transplant | 90 986 (±20%) | Gamma | [8] |
| After liver transplant | 17 612 (±20%) | Gamma | [30] |
| IL-28B testing | 67 | – | [23] |
F0, Metavir fibrosis stage 0; F1, Metavir fibrosis stage 1; F2, Metavir fibrosis stage 2; F3, Metavir fibrosis stage 3; F4, Metavir fibrosis stage 4; SVR, sustained virologic respond; HCC, hepatocellular carcinoma; DT, dual therapy; TT, triple therapy.